By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Portola Pharmaceuticals, Inc. 

270 East Grand Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-246-7000 Fax: 650-246-7376


Portola Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the development and commercialization of novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation. Its development-stage portfolio consists of the compounds including Betrixaban, a novel oral once-daily inhibitor of Factor Xa in phase three clinical trials for extended duration prophylaxis, or preventive treatment of a form of thrombosis known as venous thromboembolism, in acute medically ill patients; Andexanet alfa, a recombinant protein designed to reverse anticoagulant activity in patients treated with a Factor Xa inhibitor; and Cerdulatinib, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases, enzymes that regulate important signaling pathways.


September 2, 2003


Founder: Charles Homcy and David Philips

CEO: William Lis

CFO: Mardi Dier

CTO: R. Andrew Ramelmeier


Please click here for Portola job opportunities.


Please click here for clinical trial information.


Key Statistics

Ownership: Public

Web Site: Portola
Employees: 130
Symbol: PTLA

Start Up

Company News
Portola (PTLA) To Webcast Corporate Update On January 10, 2017 1/3/2017 7:58:54 AM
Portola (PTLA) Announces FDA Accepts New Drug Application For Priority Review And EMA Validates Marketing Authorization Application For Oral, Factor Xa Inhibitor Anticoagulant Betrixaban 12/27/2016 7:49:21 AM
Dermavant Sciences Announces Licensing Of Topical Cerdulatinib From Portola (PTLA) For Dermatologic Indications 12/21/2016 11:39:11 AM
Portola (PTLA) Enters Into $50 Million Loan Agreement With Bristol-Myers Squibb (BMY) And Pfizer (PFE) For Continued Development Of Andexxa (Andexanet Alfa) 12/19/2016 1:07:36 PM
Portola (PTLA) Announces Andexxaâ„¢ (Andexanet Alfa), Betrixaban And Cerdulatinib Data To Be Presented At 2016 American Society of Hematology Annual Meeting And Exposition 11/28/2016 7:17:39 AM
Portola (PTLA) Announces Three Phase III APEX Substudy Results Showing Further Benefits Of Treating Acute Medically Ill Patients With Extended-Duration Betrixaban 11/15/2016 8:06:16 AM
Portola (PTLA) Expands Clinical Collaboration Agreement With Daiichi Sankyo Worth Up To $25 Million To Develop Andexxa (Andexanet Alfa) In Germany 11/1/2016 10:49:57 AM
Portola (PTLA) To Announce Third Quarter 2016 Financial Results And Host Conference Call On Monday, November 7 10/31/2016 8:04:02 AM
Portola (PTLA) Submits New Drug Application To FDA For Betrixaban For Extended Duration Prophylaxis Of Venous Thromboembolism In Acute Medically Ill Patients 10/25/2016 7:49:04 AM
Portola (PTLA) Announces Upcoming Data Presentations On Andexxa (Andexanet Alfa) At Neurocritical Care Society 2016 Annual Meeting 9/13/2016 8:12:48 AM